Co-expression of CD69, CD49d, CD279 and CD20 in chronic lymphocytic leukemia cells is a new biomarker of active disease before or under therapy

Ítems similars

• New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling.
  per: Sarah Cadot, et al.
  Publicat: (2024-07-01)
• Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse
  per: Sarah Cadot, et al.
  Publicat: (2020-12-01)
• Co-expression of CD69, CD49d, CD279 and CD20 in chronic lymphocytic leukemia cells is a new biomarker of active disease before or under therapy
  per: Sarah Cadot, et al.
  Publicat: (2024-09-01)
• Overall survival outcomes with first‐line continuous ibrutinib and fixed‐duration ibrutinib‐venetoclax treatments in patients with chronic lymphocytic leukemia: Comparison with an age‐matched European population
  per: Paolo Ghia, et al.
  Publicat: (2025-10-01)
• Multiparametric analysis of CD8+ T cell compartment phenotype in chronic lymphocytic leukemia reveals a signature associated with progression toward therapy
  per: Pauline Gonnord, et al.
  Publicat: (2019-04-01)